We report a case of severe acute primary pulmonary toxoplasmosis in an immunocompetent young man living in Nice (Southern France). The Toxoplasma DNA extracted from the broncho-alveolar lavage fluid allowed a genetic characterization of the responsible strain which displayed an atypical genotype of Toxoplasma gondii. This unusual genetic composition of the parasite may have influenced, among other factors, the severity of the disease.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jinf.2005.10.026DOI Listing

Publication Analysis

Top Keywords

toxoplasma gondii
8
immunocompetent young
8
young man
8
severe pneumonia
4
pneumonia primary
4
primary infection
4
infection atypical
4
atypical strain
4
strain toxoplasma
4
gondii immunocompetent
4

Similar Publications

Concurrent Cilioretinal Artery Occlusion in Acute Toxoplasma Chorioretinitis.

Am J Ophthalmol

January 2025

Harvard Retinal Imaging Lab, Harvard Medical School, Boston, Massachusetts, USA; Retina Service, Massachusetts Eye and Ear, Boston, Massachusetts, USA. Electronic address:

View Article and Find Full Text PDF

Protection induced by recombinant vaccinia virus targeting the ROP4 of Toxoplasma gondii in mice.

Exp Parasitol

January 2025

Department of Medical Zoology, School of Medicine, Kyung Hee University, Seoul, 02447, Republic of Korea; Medical Research Center for Bioreaction to Reactive Oxygen Species and Biomedical Science Institute, Core Research Institute (CRI), Kyung Hee University, Seoul, 02447, Republic of Korea. Electronic address:

Toxoplasmosis is a parasitic disease affecting a significant portion of the global population, whose etiology can be attributed to the protozoan organism Toxoplasma gondii. Despite its public health importance, an efficacious vaccine to prevent human toxoplasmosis remains unavailable. To this end, we designed an experimental toxoplasmosis vaccine using recombinant vaccinia virus vectors (rVacv) expressing the T.

View Article and Find Full Text PDF

Knowledge of pathogen epidemiological dynamics and habitat ecological features is essential for wildlife population and health monitoring and management. Toxoplasma gondii and Neospora caninum are two broadly distributed multi-host parasites that affect both wild and domestic animals and, in the case of T. gondii, cause zoonosis.

View Article and Find Full Text PDF

Exploring the Inhibition of α-Carbonic Anhydrase by Sulfonamides: Insights into Potential Drug Targeting.

Int J Mol Sci

December 2024

Neurofarba Department, Section of Pharmaceutical Sciences, University of Florence, Via Ugo Schiff 6, Sesto Fiorentino, 50019 Florence, Italy.

, the causative agent of toxoplasmosis, is a protozoan parasite capable of infecting a wide range of hosts, posing significant health risks, particularly to immunocompromised individuals and congenital transmission. Current therapeutic options primarily target the active tachyzoite stage but are limited by issues such as toxicity and incomplete efficacy. As a result, there is an urgent need for alternative therapies that can selectively target parasite-specific mechanisms critical for metabolic processes and host-parasite interactions.

View Article and Find Full Text PDF

The Ivermectin Related Compound Moxidectin Can Target Apicomplexan Importin α and Limit Growth of Malarial Parasites.

Cells

January 2025

Nuclear Signaling Laboratory, Monash Biomedicine Discovery Institute, Department of Biochemistry and Molecular Biology, Monash University, Clayton, VIC 3800, Australia.

Signal-dependent transport into and out of the nucleus mediated by members of the importin (IMP) superfamily is crucial for eukaryotic function, with inhibitors targeting IMPα being of key interest as anti-infectious agents, including against the apicomplexan species and , causative agents of malaria and toxoplasmosis, respectively. We recently showed that the FDA-approved macrocyclic lactone ivermectin, as well as several other different small molecule inhibitors, can specifically bind to and inhibit and IMPα functions, as well as limit parasite growth. Here we focus on the FDA-approved antiparasitic moxidectin, a structural analogue of ivermectin, for its IMPα-targeting and anti-apicomplexan properties for the first time.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!